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Background and Purpose: This study was designed to evaluate the effectiveness and safety of rivaroxaban in real-world practice compared with dabigatran or with warfarin for stroke prevention in atrial fibrillation (AF) through meta-analyzing observational studies.
Methods 17 studies were included after searching in PubMed for studies reporting the comparative effectiveness and safety of rivaroxaban vs. dabigatran(n=3), rivaroxaban vs. warfarin(n=11) or both(n=3) for stroke prevention in AF. 
Results: Overall, the risks of stroke/systematic thromboembolism (TE) with rivaroxaban were similar compared with dabigatran [Stroke/TE:(1.02, 0.91-1.13, I2=70.2%, N=5)], but were significantly reduced when compared to warfarin (0.75,0.64-0.85, I2=45.1%, N=9). Major bleeding risk was significantly higher with rivaroxaban than dabigatran (1.38, 1.27-1.49, I2=26.1%, N=5), but similar to warfarin (0.99, 0.91-1.07, I2=0.0%, N=6). Rivaroxaban was associated with increased all-cause mortality and gastrointestinal bleeding (GIB), but similar risk of acute myocardial infarction (AMI) and intracranial hemorrhage (ICH) compared with dabigatran. When compared with warfarin, rivaroxaban was associated with similar risk of any bleeding, mortality and AMI, but a higher risk of GIB and lower risk of ICH.
Conclusions: In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of Stroke/TE in AF patients. Major bleeding risk was significantly higher with rivaroxaban than dabigatran, as was all-cause mortality and GIB. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in GIB and decreased risk of ICH.
Introduction

The use of oral anticoagulants (OACs) such as the Vitamin K antagonists (VKA, eg. warfarin) in patients with atrial fibrillation (AF) results in a significant reduction in stroke, ischemic stroke (IS) and systematic thromboembolism (TE), as well as all-cause mortality, when compared to placebo or control.1  However, warfarin has many limitations, including the necessity for regular anticoagulation monitoring, dietary and drug interactions, and the potential for serious bleeding if anticoagulation is poorly controlled, as reflected by a poor time in therapeutic range (TTR). ADDIN EN.CITE 2

The availability of the non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for stroke prevention in AF, and a meta-analysis of randomized clinical trials (RCTs) by Ruff et al  ADDIN EN.CITE 3 has shown that usual dose NOACs result in a significant reduction in stroke/TE and mortality with NOACs compared to warfarin, with a trend towards less major bleeding and significantly lower intracranial hemorrhage (ICH).  However, RCTs have specific inclusion/exclusion criteria, set protocol-based follow-up and perhaps represent a highly selected and controlled scenario, but still represent the gold standard of testing the effectiveness and safety of an intervention.  Based on RCT data, indirect comparisons have been published showing how the different NOACs may perform relative to each other  ADDIN EN.CITE 4, 5 but only a head-to-head RCT can definitively assess the relative efficacy and safety of one NOAC against another.








We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the reporting Meta-analyses of Observational Studies in Epidemiology (MOOSE) when performing this meta-analysis. ADDIN EN.CITE 13, 14

Two independent reviewers (Y. B. and H. D.) conducted a search of Medline and the Cochrane Library using the following items “atrial fibrillation”, “AF”, “rivaroxaban”, “dabigatran”, “warfarin”, “real-world”, “observational studies” until 4 October, 2016, respectively. We also reviewed the lists of references in eligible studies and reviews. Disagreement was resolved by consensus.

To be included in the meta-analysis, the observational studies needed to fulfill the following criteria:  (i) With OACs used for stroke prevention in patients with AF;  (ii) Available quantitative data on clinical events; (iii) Adjusted hazard ratios (HRs) between rivaroxaban vs. dabigatran, or rivaroxaban vs. warfarin for stroke prevention in AF. The following studies were excluded:
(i)	Animal based studies;
(ii)	Non-English based papers;
(iii)	Abstracts, editorials, case-reports, reviews and case series;
(iv)	Specific studies on AF patients undergoing ablation or cardioversion.
We recorded clinical events related to effectiveness outcomes as IS, TE, the combination of Stroke and TE (Stroke/TE), and acute myocardial infarction (AMI) of rivaroxaban in comparison with dabigatran or warfarin.  Separate IS, hemorrhagic stroke, stroke or TE outcomes were used instead if no data on Stroke/TE was available in the original papers. Safety outcomes were major bleeding, any bleeding, ICH, gastrointestinal bleeding (GIB) or all-cause mortality. Definitions of these effectiveness and safety outcomes were extracted from the original papers. If available, other collected study characteristics included: authors, publication year, study country, period, cohort size, percentage of low-dose rivaroxaban, percentage of low-dose dabigatran, new-users or switchers of NOACs and estimated follow-up duration. Quality score for each study was assessed by the Newcastle-Ottawa scale.15

Statistical analysis







A total of 1086 studies were initially identified (including 829 on-line and 257 from references). After screening titles and abstracts, we excluded 1007 papers and 79 remained for a detailed evaluation. Of these studies, 62 were excluded as they did not meet the inclusion criteria (6 were reviews and meta-analysis; 25 studies on OACs in specific AF populations, such as ablation or cardioversion were excluded due to their modest size and short period of follow-up (less than 30 days). Also, 12 papers lacked outcome data in AF patients. Comparison of separate data for rivaroxaban with warfarin could not be extracted from 2 papers; adjusted HRs between OACs comparisons were lacking in 16; and no separate AF data could be extracted from 1 paper with mixed disease states.  Finally, 17 observational studies ADDIN EN.CITE 7-12, 20-31 were included in our analysis, with 3 comparing rivaroxaban vs. dabigatran ADDIN EN.CITE 9-11, 11 comparing rivaroxaban vs. warfarin ADDIN EN.CITE 20-27, 29-31 and 3 evaluating both comparisons ADDIN EN.CITE 7, 8, 12. Studies with new users and switchers are shown in Supplementary Table I. Quality scoring revealed moderate-to-high scores of the included studies. The selection process and baseline characteristics of included studies are summarized in Supplementary Figure I and Tables 1 and 2. Anticipated outcomes evaluated are summarized in Supplementary Table II. The endpoints in various comparison settings are shown in Supplementary Table III.

Comparisons between Rivaroxaban and Dabigatran
Rivaroxaban was associated with a similar risk of Stroke/TE compared with dabigatran, ADDIN EN.CITE 7-11(HR: 1.02, 95% CI: 0.91-1.13, I2=70.2%, N=5) (Figure 1), with pooled rates for rivaroxaban being 0.3%/year vs. dabigatran 0.3%/year. No significant publication bias was seen among the included studies using Begg’s test (p=0.21) and Egger’s test (p=0.25). Subanalysis was performed through pooling 3 studies evaluating the IS risk between rivaroxaban and dabigatran ADDIN EN.CITE 9-11, which was non-significantly different, (HR: 0.98, 95% CI: 0.88-1.08, I2=46.0%, p=0.12), (Supplementary Figure II), with pooled rates for rivaroxaban being 0.57%/year vs. dabigatran 0.54%/year.  No significant publication bias was seen among the included studies using Begg’s test (p=0.46) and Egger’s test (p=0.08) .

The pooled rate of major bleeding was 1.45%/year for rivaroxaban and 0.55%/year for dabigatran. Major bleeding risk was significantly higher with rivaroxaban than dabigatran after pooling the five studies. ADDIN EN.CITE 7, 9-12 (HR: 1.38, 95% CI: 1.27-1.49, I2=26.1%, N=5) (Figure 2). No significant publication bias was seen among the included studies using Begg’s test (p=0.76) and Egger’s test (p=0.39).

Rivaroxaban was associated with increased risk in all-cause mortality ADDIN EN.CITE 7-10 (HR: 1.23, 95% CI: 1.12-1.33, I2=31.5%, N=4), any bleeding ADDIN EN.CITE 8-10 (HR:1.33, 95% CI:1.17-1.49, I2=74.8%, N=3) and GIB ADDIN EN.CITE 7, 9, 10 (HR: 1.33, 95% CI: 1.18-1.48, I2=58.3%, N=3), but similar risk of AMI ADDIN EN.CITE 7, 9 (HR: 0.81, 95% CI: 0.43-1.19, I2=0.0%,N=2) and ICH ADDIN EN.CITE 7, 9-11 (HR: 1.22, 95% CI: 0.85-1.59, I2=64.5%,N=4) when compared with dabigatran. 

Comparisons between Rivaroxaban and Warfarin
The pooled annual rate of Stroke/SE was 2.57%/year for rivaroxaban and 2.86%/year for warfarin in AF patients. (HR: 0.75, 95% CI: 0.64-0.85, I2=45.1%, N=9). ADDIN EN.CITE 7, 8, 21, 22, 25, 26, 29-31 (Figure 3). Subgroup analysis was performed through meta-analyzing 6 observational studies evaluating IS risk between rivaroxaban and warfarin ADDIN EN.CITE 20, 22, 25, 26, 30, 31, and rivaroxaban was associated with lower risk of IS (HR: 0.86, 95% CI: 0.75-0.97, I2=0.0%, N=6) (Supplementary Figure III). No publication bias was seen according to Begg’s test (IS: p=1.0; Stroke/SE: p=0.37) and Egger’s test (IS: p= 0.87; Stroke/SE: p=0.1).

The pooled rate of major bleeding was 3.70%/year for rivaroxaban and 3.73%/year for warfarin, based on meta-analysis of 6 studies (HR:0.99, 95% CI: 0.91-1.07, I2=0.0%, N= 6). ADDIN EN.CITE 7, 12, 24-26, 30 (Figure 4) No publication bias were seen in this study according to Begg’s test (p=0.26) and Egger’s test (p=0.22).

Rivaroxaban was associated with similar risk of any bleeding (HR:1.01, 95% CI: 0.94-1.08, I2=0.0%, N=5) ADDIN EN.CITE 8, 21, 24, 26, 29, AMI (HR: 0.73, 95% CI:  0.30-1.15, I2=0.0%, N=2) ADDIN EN.CITE 7, 21 and all-cause mortality (HR: 1.04, 95% CI:  0.64-1.44, I2=92.7%, N=3)  ADDIN EN.CITE 7, 8, 26 compared with warfarin. The risk of ICH was significantly lower (HR: 0.54, 95% CI: 0.43-0.64, I2=63.6%, N=6) ADDIN EN.CITE 7, 22, 24-26, 30, but risk of GIB was significantly higher (HR: 1.2, 95% CI: 1.07-1.33, I2=27.5%, N=5) ADDIN EN.CITE 7, 20, 24, 25, 30 with rivaroxaban compared to warfarin.

Sensitivity Analysis
The results were consistent among studies for both low-dose and high-dose rivaroxaban vs. dabigatran comparisons on the clinical outcomes, except for the endpoint of AMI, where studies did not report on low-dose rivaroxaban vs. dabigatran comparisons (Supplementary Figure IV).

The risk of Stroke/TE was similar (1.08, 0.95-1.21, I2=70.7%, N=4) ADDIN EN.CITE 7-10 when we conducted sensitivity analysis including studies with NOAC (Rivaroxaban vs. Dabigatran) new-users. When sensitivity analysis was performed for new-users of rivaroxaban vs. warfarin, there was general consistency with the summary comparisons. Although new users of rivaroxaban showed significant reductions in IS (HR 0.85, 0.72-0.97), Stroke/TE (0.78, 0.69-0.87) and ICH (-0.64,0.51-0.77). No significant difference in major bleeding, any bleeding, mortality and GIB was evident amongst new users (Supplementary Figure V, Table I and Table III).

For other endpoints, the results were broadly similar with the summary analysis except for an increased risk of mortality in low-dose rivaroxaban and similar risk of IS in high-dose rivaroxaban, when compared with warfarin (Supplementary Figure VI).




This systematic review and meta-analysis using real-world observational studies has the following principal findings: (i) When compared to dabigatran, rivaroxaban had similar risks of IS, Stroke/TE, AMI and ICH, but increased risks of major bleeding, any bleeding and GIB; (ii) When compared with warfarin, rivaroxaban was associated with lower risks of IS, Stroke/TE and ICH, with an increased risk of GIB, and similar risks of major bleeding, any bleeding and mortality; and (iii) New users of rivaroxaban had superiority to warfarin for the prevention of IS and Stroke/TE and a lower risk of ICH, but similar risk of GIB.

Our results are partially discordant from previous indirect comparisons of R vs. D for the risk of Stroke/TE and major bleeding in AF patients. ADDIN EN.CITE 4, 5  The large randomized trials ADDIN EN.CITE 32  ADDIN EN.CITE 33 differed in inclusion criteria based on stroke risk profile. Bias could easily be produced with unadjusted confounding, which was considered but unresolved in previous indirect comparison analyses.  In contrast, our included ‘real-world’ studies have used adjusted HRs and compared subjects with broadly similar stroke risks taking rivaroxaban or dabigatran during the same time period within each study. 

Different percentages of patients received low-dose NOACs in the published real-world studies (eg. for low-dose rivaroxaban and dabigatran: nearly 90% in Hernandez et al,10 and about 30% in Chan et al ADDIN EN.CITE 7). However, there were generally consistent results between low-dose and high-dose rivaroxaban vs. dabigatran in most clinical outcomes.   

Our findings provide an estimate of the various anticipated outcomes of rivaroxaban when used in everyday clinical practice when compared to warfarin. Rivaroxaban was a non-inferior alternative to warfarin in IS, Stroke/TE prevention. While the results were similar to the summary data, low-dose and high-dose rivaroxban vs. warfarin data were limited when the sensitivity analysis was done.  Our results also provide some insights regarding whether to switch patients from warfarin to NOACs. Rivaroxaban new-users showed superior effectiveness to warfarin for IS and Stroke/TE prevention, but switchers showed similar risks. The exact reason(s) are unknown, but could be partly explained by the assumption of poor compliance for OACs in those switched from warfarin, because usually AF patients would be transferred to take rivaroxaban for poor TTR of warfarin. Importantly, our study reflects real-world clinical practice, given that patients included in ROCKET-AF had a higher stroke risk profile. ADDIN EN.CITE 33

In safety evaluations, both ROCKET-AF ADDIN EN.CITE 33 and our analysis have shown patients treated with rivaroxaban have increased GIB risk and decreased ICH risk compared to warfarin. An ancillary analysis of ROCKET-AF has ascribed the higher GIB to a history of GIB or older age.34 Our results could partially provide supportive evidence for this hypothesis, as new rivaroxaban users had a similar risk of GIB compared with warfarin users, with GIB risk evaluated using HRs adjusted for age and bleeding history, within the included studies. ADDIN EN.CITE 20, 24  ICH is the most feared complication for OACs and consistent with trial data, we show that rivaroxaban users had significantly less ICH compared to warfarin.

Limitations and Strengths
To our knowledge, this is the first meta-analysis of the head-to-head comparison among NOACs. There are several limitations inherent to the interpretation of these results. First, only studies in English were included for the analysis which increased the potential language bias. However, a tendency towards publication in English journals minimized this effect.35 Second, high heterogeneity across studies in Stroke/TE should not be neglected, though a random-effects model was used for adjustment. Nonetheless, results were broadly similar even if sensitivity analysis (eg. new-users or different dose prescription) and subgroup analysis in IS, which decreased the heterogeneity, were performed. Third, different inclusion/exclusion criteria and follow-up periods in the included studies led to high heterogeneity, so it is necessary to cautiously interpret the noticeable differences in some event rates between the rivaroxaban vs. dabigatran cohort, and rivaroxaban vs. warfarin comparisons (eg. Stroke /TE rate 0.3%/year in the former vs. 2.8%/year in the latter; major bleeding was 1.45%/year in the former vs. 3.89%/year in the latter). To provide some perspective, we also show numbers needed to treat and numbers needed to harm for the absolute effectiveness and safety comparisons in Supplementary Table IV. Fourth, inherent limitations in the majority of meta-analysis, such as lack of access to raw data and the variety in definitions of outcomes in the included studies are unavoidable. However, we have enhanced the robustness of the analysis through extracting the effect sizes with adjusted HRs from the original studies. Indeed, low heterogeneity in the safety evaluations enhances the clinical applicability of our observations. No publication bias and the moderate-to-high quality scores according to Newcastle-Ottawa scale both increase the reliability of the pooled estimate.  Finally, the analysis covers the whole population of AF patients and no separate outcome information could be extracted for some subgroups, eg. patients with TIA or prior stroke. 

Conclusions
In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran for the prevention of IS and Stroke/TE, but was more effective than warfarin for stroke prevention in AF patients. Major bleeding risk was significantly higher with rivaroxaban than dabigatran, as was all-cause mortality and GIB. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in GIB and decreased risk of ICH. 
Hence, the risks and benefits of rivaroxaban use should be carefully accounted for, especially the individual’s risk of GIB. Based on the real-world evidence up to date, rivaroxaban was not superior to dabigatran for stroke prevention in AF patients, but had more bleeding risks.  
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Table 1 Baseline characteristics in Rivaroxaban versus Dabigatran studies
Author, year	Region	Enrolled Period 	Cohort size	LD-R(%)	LD-D(%)	eFollow-up
Chan,2016 ADDIN EN.CITE 7	Taiwan	Feb-Dec, 2013	9,837	87	90	1 y
Hernandez,201610	US	Nov, 2011-Dec, 2013	17,507	30.7	24.8	1 y
Graham,2016 ADDIN EN.CITE 9	US	Nov, 2011-Jun, 2014	118,891	0	0	0.3 y
Lip,201612	US	Jan, 2012-Dec, 2014	46,803	19.6	10.6	0.5 y
Noseworthy,201611	US	Oct, 2010- Feb, 2015	31,574	23.1	9.9	NA
Gorst-Rasmussen, 20168	Denmark	Feb, 2012-Jul, 2014	113,13	32.3	40.3	1.08 y

HD-D, high-dose dabigatran; HD-R: high-dose rivaroxaban; LD-D, low-dose dabigatran; LD-R, low-dose rivaroxaban; 
eFollow-up, estimated follow-up; y, years ;NA, not available.


Table 2 Baseline Characteristics in Rivaroxaban versus Warfarin studies
Author, year	Study design	Region	Enrolled period	Cohort size	LD-R(%)	eFollow-up
Bouillon, 201521	RC	France	Jan 2011-Nov 2012	17,410	NA	0.8y
Coleman, 201622	RC	US	Jan 2012-Oct 2014	38,831	17.3	NA
Lip, 201627	RC	US	Jan-Dec 2013	29,338	NA	0.3y
Abraham, 2016 ADDIN EN.CITE 20	RC	US	Nov 2010-Sep 2013	219,027	NA	NA
Maura G, 2015 ADDIN EN.CITE 29	RC	France	Jul-Nov 2012;	32,807	38.5	0.2y
Coleman, 201523	RC	Germany	Jan 2012-Oct 2013	5,108	NA	0.5y
Halvorsen, 2016 ADDIN EN.CITE 24	registry	Norway	Jan 2013-Jun 2015	32,675	27	0.5y

Chan YH, 2016 ADDIN EN.CITE 7	RC	Taiwan	Feb 2013-Dec 2013	304,252	87	1 y
Larsen, 2016 ADDIN EN.CITE 26	RC	Denmark	Aug 2011-Oct 2015	61 ,678	0	1.9 y
Yao X, 2016 ADDIN EN.CITE 30	RC	US	Oct 2010-Jun 2015	125,243	21.5	0.6 y
Laliberte, 2014 ADDIN EN.CITE 25	RC	US	May 2011-July 2012	30,479	NA	0.3y
Lip, 201612	RC	US	Jan 2012-Dec 2014	33262	NA	0.5y
Gorst-Rasmussen,20168	registry	Denmark	Feb 2012-Jul 2014	22,358	32.3	1.08y
Staerk,2016 ADDIN EN.CITE 31	registry	Denmark	2011-2015	43,299	NA	0.6y
Data were presented as mean or median; RC, retrospective cohort; NA, not available; 




Figure 1 Rivaroxaban compared with Dabigatran in risk of Stroke/TE in AF patients. 
IS, ischemic stroke; TE, thromboembolism; LD,low-dose; HD, high-dose; BD, both-dose; AF, atrial fibrillation.

Figure 2 Rivaroxaban compared with Dabigatran in risk of major bleeding in AF patients. 
AF, atrial fibrillation; ECH, extracranial hemorrhage.

Figure 3 Rivaroxaban compared with Warfarin in risk of Stroke/TE in AF patients. 
IS, ischemic stroke; TE, thromboembolism; AF, atrial fibrillation.














Rivaroxaban vs. Dabigatran or warfarin in ‘real-world’ studies of stroke prevention in atrial fibrillation: Systematic review and meta-analysis

















New starters and Switchers in Rivaroxaban versus Warfarin studies





Abraham,2016 ADDIN EN.CITE 4	+		
Maura,2015 ADDIN EN.CITE 5	+		
Coleman,20156	+		
Halvorsen,2016 ADDIN EN.CITE 7	+		
Chan,2016 ADDIN EN.CITE 8			+
Larsen,2016 ADDIN EN.CITE 9	+		
Yao,2016 ADDIN EN.CITE 10	+	+	+
Laliberte,2014 ADDIN EN.CITE 11			+
Lip,201612	+		
Gorst-Rasmussen,201613	+		





Table II Various outcomes included in studies of Rivaroxaban versus Warfarin 

Author,year	IS	Stroke/TE	major bleeding	any bleeding	AMI	ICB	GIB	All-cause mortality	Other clinical events
Bouillon,20151		+		+	+				composite events
Coleman, 20162	+					+			Combined IS and ICH
Lip,20163			+						
Abrham,2016 ADDIN EN.CITE 4	+						+		
Maura, 2015 ADDIN EN.CITE 5		+		+					IS/TE/death
									Hospitalized for bleeding/death
Coleman, 20156									Composite end 
Halvorsen, 2016 ADDIN EN.CITE 7			+	+		+	+		CRNM
Chan, 2016 ADDIN EN.CITE 8		+		+	+	+	+	+	
Larsen, 2016 ADDIN EN.CITE 9	+	+	+	+		+		+	IS/TE/death
Yao X, 2016 ADDIN EN.CITE 10	+	+	+			+	+		hemorrhagic stroke




									PE with or without DVT
Lip, 201612			+						
Gorst-Rasmussen, 201613		+		+				+	net clinical benefit
Staerk,2016 ADDIN EN.CITE 14	+	+				+			
IS, ischemic stroke; TE, thromboembolism; AMI, acute myocardial infarction; GIB, gastrointestinal bleeding; ICB, intracranial bleeding; CRNM, clinically relevant non-major bleeding; VTE, venous thromboembolism; DVT, deep venous thromboembolism; PE, pulmonary embolism.














IS, ischemic stroke; TE, thromboembolism; AMI, acute myocardial infarction; GIB, gastrointestinal bleeding; ICH, intracranial hemorrhage; 
R vs. D, rivaroxaban versus dabigatran; R vs. W, rivaroxaban versus warfarin; R vs. D(LD), low-dose rivaroxaban versus low-dose dabigatran;
R vs. D (HD), high-dose rivaroxaban versus high-dose dabigatran; R vs. W(LD), low-dose rivaroxaban versus warfarin; R vs. D (HD), high-dose rivaroxaban versus warfarin; R vs. W(New), rivaroxaban new-users versus warfarin; R vs. W(Switcher), rivaroxaban switcher versus warfarin; 











Table IV Number needed to treat or number needed to harm of rivaroxaban compared with dabigatran or warfarin on the risk of stroke/systematic thromboembolism and major bleeding 


















Figure I Study selection process.






Figure II Rivaroxaban compared with Dabigatran for risk of IS in AF patients. 







Figure III Rivaroxaban compared with Wafarin in risk of IS in AF patients.








Figure IV Comparisons between HD- Rivaroxaban vs. HD- Dabigatran and LD-Rivaroxaban vs. LD-Dabigatran in various outcomes in AF patients.








Figure V Rivaroxaban new users/switchers compared with warfarin in various outcomes in AF patients. 








Figure VI Rivaroxaban at different doses compared with warfarin for various outcomes in AF patients. 

IS, ischemic stroke; TE, thromboembolism; AMI, acute myocardial infarction; ICH, intracranial hemorrhage; HR, hazard ratio.								References
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